Glenmark Generics Inc., USA a subsidiary of Glenmark Generics has been granted tentative approval for Rizatriptan Benzoate tablets from the United States Food and Drug Administration (USFDA), its generic version of Merck’s Maxalt tablets.
According to IMS Health for the 12 month period ending June 2012, Rizatriptan Benzoate immediate release tablets achieved sales of $ 315 million.
Glenmark’s current portfolio consists of 81 products authorized for distribution in the U.S mark place and 41 ANDA’s pending approval with the U.S. FDA.
Glenmark Generics is a subsidiary of Glenmark Pharmaceuticals (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries.
